Objective: The Wada test is used to evaluate language lateralization and memory performance after inactivation of an isolated cerebral hemisphere. Methohexital a short-acting barbiturate has a history of use to induce interictal discharges during intraoperative corticography. We report a new finding of activation of lateralized periodic discharges (LPDs) after Methohexital injection.
Methods: We retrospectively reviewed 174 consecutive adult patients who underwent Wada testing in preparation for epilepsy surgery (N = 129, 74%) or brain tumor resection (N = 45, 26%) at the University of Michigan to determine the frequency of induced periodic discharges by methohexital.
Results: Four epilepsy patients (2.29%) had methohexital-induced LPDs within a median of 2 s (1-99 s) of the injection and lasting a median of 4 min (3-10 min) after a total of 7 injections. All LPDs occurred ipsilateral to the injection hemisphere in the known region of interictal epileptiform discharges. LPDs were not induced in brain tumor patients. In one patient, LPDs occurred during memory testing, and this patient's memory performance was below expectation based on pre-test neuropsychological testing.
Conclusions: Methohexital can induce LPDs in ipsilateral hemisphere and that can potentially affect memory performance.
Significance: This observation indicates that concurrent EEG monitoring during the Wada test is important and that induced discharges should be considered when interpreting Wada test results.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8361030 | PMC |
http://dx.doi.org/10.1016/j.cnp.2021.07.002 | DOI Listing |
Commun Chem
January 2025
Chemistry of Functional Molecules, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.
Psoralen-conjugated triplex-forming oligonucleotides (Ps-TFOs) have been employed for the photodynamic regulation of gene expression by the photo-cross-linking of psoralen with the target DNA. However, stable triplex formation requires a consecutive purine base sequence in one strand of the target DNA duplexes. The pyrimidine-base interruption in the consecutive purine base sequence drastically decreases the thermodynamic stability of the corresponding triplex, which hampers the TFO application.
View Article and Find Full Text PDFClin Chem Lab Med
January 2025
X-Pertise Consulting, Mittelhausbergen, France.
The presence of letrozole, an aromatase inhibitor, in an athlete's sample constitutes one of the more frequent anti-doping rules violation. It is possible to challenge this violation but it is the athletes who have to demonstrate their innocence. The conditions to evidence/establish the absence of fault or negligence hinge on two points: 1.
View Article and Find Full Text PDFJ Appl Microbiol
January 2025
Graduate School of Human Life and Ecology, Osaka Metropolitan University, 3-3-138, Sugimoto, Sumiyoshi-Ku, Osaka 558-8585, Japan.
Aims: To investigate the effects of Lactococcus lactis subsp. lactis strains LL100933 and LL12007 on the host defense mechanisms of Caenorhabditis elegans against pathogenic infections and stressors.
Methods And Results: C.
Osteoarthr Cartil Open
March 2025
Graduate School of Health Sciences, Morinomiya University of Medical Sciences, Osaka, Japan.
Objective: To investigate whether there is a difference in hardness and hemoglobin concentration changes in the infrapatellar fat pad (IFP) during isometric quadriceps exercise (IQE) in patients with knee osteoarthritis (KOA) between those with and without knee extension limitation.
Design: In this cross-sectional study, data were collected at an orthopedic clinic from March 2022 to April 2023. Among patients diagnosed with KOA, those with knee joint extension range of motion <0° and >0° were defined as the limited group (n = 16) and non-limited group (n = 13), respectively.
Lancet
January 2025
Department of Diagnostic and Interventional Radiology, University of Pisa School of Medicine, Pisa, Italy.
Background: Transarterial chemoembolisation (TACE) is standard of care for patients with unresectable hepatocellular carcinoma that is amenable to embolisation; however, median progression-free survival is still approximately 7 months. We aimed to assess whether adding durvalumab, with or without bevacizumab, might improve progression-free survival.
Methods: In this multiregional, randomised, double-blind, placebo-controlled, phase 3 study (EMERALD-1), adults aged 18 years or older with unresectable hepatocellular carcinoma amenable to embolisation, an Eastern Cooperative Oncology Group performance status of 0 or 1 at enrolment, and at least one measurable intrahepatic lesion per modified Response Evaluation Criteria in Solid Tumours (RECIST) were enrolled at 157 medical sites including research centres and general and specialist hospitals in 18 countries.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!